Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-08-15
2010-02-09
Haddad, Maher M (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S387700, C530S388100, C530S388220, C530S391100
Reexamination Certificate
active
07659374
ABSTRACT:
The present invention relates to novel Fc variants that immuno-specifically bind to an Eph receptor. The Fc variants comprise a binding region that immunospecifically binds to an Eph receptor and an Fc region that further comprises at least one novel amino acid residue which may provide for enhanced effector function. More specifically, this invention provides Fc variants that have modified binding affinity to one or more Fc ligand (e.g., FcγR, C1q). Additionally, the Fc variants have altered antibody-dependent cell-mediated cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) activity. The invention further provides methods and protocols for the application of said Fc variants that immunospecifically bind to an Eph receptor, particularly for therapeutic purposes.
REFERENCES:
patent: 5624821 (1997-04-01), Winter et al.
patent: 5635177 (1997-06-01), Bennett et al.
patent: 5770195 (1998-06-01), Hudziak et al.
patent: 5869046 (1999-02-01), Presta et al.
patent: 5885573 (1999-03-01), Bluestone et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6277375 (2001-08-01), Ward et al.
patent: 6737056 (2004-05-01), Presta et al.
patent: 6927203 (2005-08-01), Kinch et al.
patent: 7101976 (2006-09-01), Kinch et al.
patent: 7192698 (2007-03-01), Kinch et al.
patent: 2001/0036459 (2001-11-01), Ravetch
patent: 2002/0147311 (2002-10-01), Gillies et al.
patent: 2003/0157108 (2003-08-01), Presta
patent: 2003/0190311 (2003-10-01), Dall'Acqua et al.
patent: 2004/0002587 (2004-01-01), Watkins et al.
patent: 2004/0028685 (2004-02-01), Kinch et al.
patent: 2004/0091486 (2004-05-01), Kinch et al.
patent: 2004/0106132 (2004-06-01), Huang et al.
patent: 2004/0132101 (2004-07-01), Lazar et al.
patent: 2004/0234520 (2004-11-01), Aguet
patent: 2005/0032114 (2005-02-01), Hinton
patent: 2005/0037000 (2005-02-01), Stavenhagen
patent: 2005/0049176 (2005-03-01), Kiener et al.
patent: 2005/0054832 (2005-03-01), Lazar et al.
patent: 2005/0059592 (2005-03-01), Kiener et al.
patent: 2005/0147593 (2005-07-01), Kinch
patent: 2005/0152899 (2005-07-01), Kinch et al.
patent: 2005/0153923 (2005-07-01), Kinch
patent: 2005/0215768 (2005-09-01), Armour
patent: 2005/0244403 (2005-11-01), Lazar et al.
patent: 2006/0040325 (2006-02-01), Wu et al.
patent: 2006/0121043 (2006-06-01), Kinch et al.
patent: 2006/0122138 (2006-06-01), Kinch et al.
patent: 2006/0235208 (2006-10-01), Lazar et al.
patent: 1135153 (2005-04-01), None
patent: WO-94-29351 (1994-12-01), None
patent: WO-95-27061 (1995-10-01), None
patent: WO-98-23289 (1998-06-01), None
patent: WO-99-58572 (1999-11-01), None
patent: WO-00-30673 (2000-06-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO-01-12172 (2001-02-01), None
patent: WO-01-12840 (2001-02-01), None
patent: WO-03-074679 (2003-09-01), None
patent: WO-03-094859 (2003-11-01), None
patent: WO-03-099313 (2003-12-01), None
patent: WO-2004-014292 (2004-02-01), None
patent: WO 2004/029207 (2004-04-01), None
patent: WO-2005-047327 (2005-05-01), None
patent: WO2005051307 (2005-06-01), None
patent: WO-2005-070963 (2005-08-01), None
patent: WO-2006-023403 (2006-03-01), None
patent: WO 2006/023420 (2006-03-01), None
patent: WO-2007-075706 (2007-07-01), None
Alegre, M. L., et al. “A Non-Activating “Humanized” Anti-CD3 Monoclonal Antibody Retains Immunosuppressive Properties in Vivo.”Transplantation(1994) 57: 1537-43.
Armour, K. L., et al. “Recombinant Human IgG Molecules Lacking Fcgamma Receptor I Binding and Monocyte Triggering Activities.”Eur.J.Immunol.(1999) 29: 2613-24.
Bruggemann, M., et al. “Comparison of the Effector Functions of Human Immunoglobulins using a Matched Set of Chimeric Antibodies.”J.Exp.Med.(1987) 166: 1351-61.
Clynes, R., et al. “Fc Receptors are Required in Passive and Active Immunity to Melanoma.”Proc.Natl.Acad.Sci.U.S.A.(1998) 95: 652-6.
Dall'Acqua, W. F., et al. “Modulation of the Effector Functions of a Human IgG1 through Engineering of its Hinge Region.”J.Immunol.(2006) 177: 1129-38.
Duncan, A. R., et al. “Localization of the Binding Site for the Human High-Affinity Fc Receptor on IgG.”Nature(1988) 332: 563-4.
Ghetie, V., et al. “Increasing the Serum Persistence of an IgG Fragment by Random Mutagenesis.”Nat.Biotechnol.(1997) 15: 637-40.
Hutchins, J. T., et al. “Improved Biodistribution, Tumor Targeting, and Reduced Immunogenicity in Mice with a Gamma 4 Variant of Campath-1H.”Proc.Natl.Acad.Sci.U.S.A.(1995) 92: 11980-4.
Idusogie, E. E., et al. “Engineered Antibodies with Increased Activity to Recruit Complement.”J.Immunol.(2001) 166: 2571-5.
Idusogie, E. E., et al. “Mapping of the Clq Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc.”J.Immunol.(2000) 164: 4178-84.
Jefferis, R., et al. “Interaction Sites on Human IgG-Fc for FcgammaR: Current Models.” Immunol.Lett. (2002) 82: 57-65.
Jefferis, R., et al. “Modulation of Fc(Gamma)R and Human Complement Activation by IgG3-Core Oligosaccharide Interactions.”Immunol.Lett.(1996) 54: 101-4.
Jefferis, R., et al. “Recognition Sites on Human IgG for Fc Gamma Receptors: The Role of Glycosylation.”Immunol.Lett.(1995) 44: 111-7.
Lund, J., et al. “Multiple Interactions of IgG with its Core Oligosaccharide can Modulate Recognition by Complement and Human Fc Gamma Receptor I and Influence the Synthesis of its Oligosaccharide Chains.”J.Immunol.(1996) 157: 4963-9.
Lund, J., et al. “Oligosaccharide-Protein Interactions in IgG can Modulate Recognition by Fc Gamma Receptors.”FASEB J.(1995) 9: 115-9.
Lund, J., et al. “Multiple Binding Sites on the CH2 Domain of IgG for Mouse Fc Gamma R11.”Mol.Immunol.(1992) 29: 53-9.
Lund, J., et al. “Human Fc Gamma RI and Fc Gamma RII Interact with Distinct but Overlapping Sites on Human IgG.”J.Immunol.(1991) 147: 2657-62.
MedImmune Inc. “International Preliminary Report on Patentability and Written Opinion of the International Searching Authority for PCT/US2005/028839.” : 1-6.
Patel, A. K., et al. “An Improved Assay for Antibody Dependent Cellular Cytotoxicity Based on Time Resolved Fluorometry.”J.Immunol.Methods(1995) 184: 29-38.
Presta, L. G., et al. “Engineering Therapeutic Antibodies for Improved Function.”Biochem.Soc.Trans.(2002) 30: 487-90.
Reddy, M. P., et al. “Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4.”J.Immunol.(2000) 164: 1925-33.
Shields, R. L., et al. “Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human Fcgamma RIII and Antibody-Dependent Cellular Toxicity.”J.Biol.Chem.(2002) 277: 26733-40.
Shields, R. L., et al. “High Resolution Mapping of the Binding Site on Human IgG1 for Fc Gamma RI, Fc Gamma RII, Fc Gamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc Gamma R.”J.Biol.Chem.(2001) 276: 6591-604.
Wilkinson, R. W., et al. “Antibody-Dependent Cell-Mediated Cytotoxicity: A Flow Cytometry-Based Assay using Fluorophores.”J.Immunol.Methods(2001) 258: 183-91.
Wisecarver, J., et al. “A Method for Determination of Antibody-Dependent Cellular Cytotoxicity (ADCC) of Human Peripheral Mononuclear Cells.”J.Immunol.Methods(1985) 79: 277-82.
Xu, D., et al. “In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies.”Cell.Immunol.(2000) 200: 16-26.
Alves, P. M., et al. “EphA2 as Target of Anticancer Immunotherapy: Identification of HLA-A*0201-Restricted Epitopes.” Cancer research 63.23 (2003): 8476-80.
Cai, W., et al. “Quantitative radioimmunoPET Imaging of EphA2 in Tumor-Bearing Mice.” Eur.J.Nucl.Med.Mol.Imaging (2007), 34: 2024-2036.
Carles-Kinch, K., et al. “Antibody Targeting of the EphA2 Tyrosine Kinase Inhibits Malignant Cell Behavior.” Cancer research 62.10 (2002): 2840-7.
Che
Gao Changshou
Wu Herren
Dahle Chun
Haddad Maher M
MedImmune LLC
LandOfFree
Eph receptor Fc variants with enhanced antibody dependent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Eph receptor Fc variants with enhanced antibody dependent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Eph receptor Fc variants with enhanced antibody dependent... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4223547